Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. Nagasaka M, Ou SI. J Thorac Oncol 2021;16:532-536.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nagasaka M, Ou SI. Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. J Thorac Oncol 2021;16:532-536.
PMID: 33781444